OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
An investigative combination therapy combining chemotherapy and immunotherapy of adoptive cell transfer with tumor infiltrating lymphocytes, followed by interleukin-2, is labor-intensive but a feasible therapy with a high response rate in treated patients, according to researchers.
Related Content:
News